Immune Design Corp. (NASDAQ:IMDZ) Insider Sells $114,300.00 in Stock
Immune Design Corp. (NASDAQ:IMDZ) insider Wayne Gombotz sold 10,000 shares of Immune Design Corp. stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $11.43, for a total transaction of $114,300.00. Following the completion of the transaction, the insider now directly owns 33,054 shares of the company’s stock, valued at $377,807.22. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of Immune Design Corp. (IMDZ) traded up 0.239% during trading on Friday, hitting $10.475. 82,634 shares of the company’s stock were exchanged. The company has a 50-day moving average of $9.47 and a 200-day moving average of $7.03. Immune Design Corp. has a 12-month low of $4.50 and a 12-month high of $13.05. The company’s market cap is $268.36 million.
Immune Design Corp. (NASDAQ:IMDZ) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.11. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 55.70%. The business had revenue of $0.73 million during the quarter, compared to analyst estimates of $1.50 million. On average, equities analysts expect that Immune Design Corp. will post ($2.30) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Immune Design Corp. (NASDAQ:IMDZ) Insider Sells $114,300.00 in Stock” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/04/immune-design-corp-nasdaqimdz-insider-sells-114300-00-in-stock.html.
Several large investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. raised its stake in Immune Design Corp. by 11.6% in the first quarter. Victory Capital Management Inc. now owns 1,937,554 shares of the biotechnology company’s stock worth $13,175,000 after buying an additional 202,149 shares during the last quarter. Renaissance Technologies LLC raised its stake in Immune Design Corp. by 170.0% in the first quarter. Renaissance Technologies LLC now owns 111,740 shares of the biotechnology company’s stock worth $760,000 after buying an additional 70,351 shares during the last quarter. Wells Fargo & Company MN raised its stake in Immune Design Corp. by 46.5% in the first quarter. Wells Fargo & Company MN now owns 148,887 shares of the biotechnology company’s stock worth $1,012,000 after buying an additional 47,266 shares during the last quarter. Personal Capital Advisors Corp acquired a new stake in Immune Design Corp. during the second quarter worth about $356,000. Finally, Trexquant Investment LP acquired a new stake in Immune Design Corp. during the first quarter worth about $183,000. 50.60% of the stock is owned by institutional investors and hedge funds.
A number of brokerages have commented on IMDZ. ValuEngine raised shares of Immune Design Corp. from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Zacks Investment Research raised shares of Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research note on Tuesday, July 18th. Jefferies Group LLC reissued a “buy” rating and issued a $18.00 price objective on shares of Immune Design Corp. in a research note on Wednesday, June 28th. Finally, Cowen and Company reissued a “buy” rating on shares of Immune Design Corp. in a research note on Tuesday, June 6th.
About Immune Design Corp.
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Stock Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related stocks with our FREE daily email newsletter.